1. **Background:**
Kynmobi is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of “off” episodes in patients with Parkinson’s disease.

Coverage will be provided for members who meet the following criteria.

2. **Coverage Criteria**:

<table>
<thead>
<tr>
<th>Program Number</th>
<th>2020 P 2229-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program</td>
<td>Prior Authorization/Medical Necessity</td>
</tr>
<tr>
<td>Medication</td>
<td>Kynmobi™ (apomorphine) sublingual film</td>
</tr>
<tr>
<td>P&amp;T Approval Date</td>
<td>12/2020</td>
</tr>
<tr>
<td>Effective Date</td>
<td>3/1/2021; Oxford only: 3/1/2021</td>
</tr>
</tbody>
</table>

1. **Initial Authorization**

    a. **Kynmobi** will be approved based on **all** of the following criteria:

    - **Diagnosis of Parkinson’s disease**

    - **AND-**

    - **b. Kynmobi** will be used as intermittent treatment for OFF episodes

    - **AND-**

    - **c. Prescribed by or in consultation with a neurologist or specialist in the treatment of Parkinson’s disease**

    - **AND-**

    - **d. Patient is currently on a stable dose of a carbidopa/levodopa-containing medication and will continue receiving treatment with a carbidopa/levodopa-containing medication while on therapy**

    - **AND-**

    - **e. Patient continues to experience ≥ 2 hours of OFF time per day despite optimal management of carbidopa-levodopa therapy including both of the following:**

    1. Taking carbidopa/levodopa on an empty stomach or at least one half-hour
or more before or one hour after a meal or avoidance of high protein diet

-AND-

(2) Dose and dosing interval optimization

-AND-

f. History of failure, contraindication, or intolerance to two anti-Parkinson’s disease therapy from the following adjunctive pharmacotherapy classes (trial must be from two different classes):

(1) Dopamine agonists (e.g., pramipexole, ropinirole)
(2) Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
(3) Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)

Authorization will be issued for 6 months.

B. Reauthorization

1. Kynmobi will be approved based on the following criterion:

   a. Documentation of positive clinical response to Kynmobi therapy

   -AND-

   b. Patient will continue to receive treatment with a carbidopa/levodopa-containing medication

   Authorization will be issued for 12 months.

a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

3. Additional Clinical Rules:
   • Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
   • Supply limits may be in place.

© 2020 UnitedHealthcare Services, Inc.
4. **References:**


<table>
<thead>
<tr>
<th>Program</th>
<th>Prior Authorization/Medical Necessity – Kynmobi (apomorphine) sublingual film</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change Control</td>
<td></td>
</tr>
<tr>
<td>12/2020</td>
<td>New program</td>
</tr>
</tbody>
</table>